Acarix is a Swedish medical device company that innovates solutions for rapid AI-based Coronary Artery Disease (CAD) rule-out.
The CE-mark approved and FDA De Novo cleared Acarix CADScor®System is for patients experiencing stable chest pain with suspected CAD and is designed to help reduce millions of unnecessary and costly diagnostic procedures.2 CADScor®System calculates a patient-specific CAD-score non-invasively in 10 minutes with at least 96% confidence (Negative Predictive Value).1
Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX).
Our mission is to create a paradigm shift in cardiovascular diagnostics through rapid, reliable and reassuring evaluation of chest pain patients with suspected heart disease.
Our vision is that everyone who needs a CADScor®System assessment should be able to have one in a timely manner.
An AI-powered acoustic diagnostic aid to rule out significant coronary artery disease in 10 minutes.
Please visit our contact page to get in touch.
- User manual US-FDA v.12.Y, prevalence 10,7%
- Shaw LJ, Marwick TH, Zoghbi WA, Hundley WG, Kramer CM, Achenbach S, Dilsizian V, Kern MJ, Chandrashekhar Y, Narula J. Why all the focus on cardiac imaging? JACC Cardiovasc Imaging. 2010 Jul;3(7):789-94. doi: 10.1016/j.jcmg.2010.05.004. PMID: 20633864.